HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.

Biocytogen Pharmaceuticals-B (02315) is up nearly 6%. As of the time of writing, it has risen by 5.85%, trading at HK$58.8, with a transaction volume of HK$53.2707 million. In terms of news, Biocytogen Pharmaceuticals announced it expects to achieve operating revenue of between RMB 936 million and RMB 946 million for the first half of 2026, marking a year-on-year increase of 50.80%-52.41%; the net profit attributable to shareholders of the parent company is estimated to be between RMB 236 million and RMB 246 million, representing a year-on-year growth of 392%-413%. The performance fluctuations are primarily attributed to the company's reliance on a forward-looking research and development layout and a high-quality customer network, allowing its two main business lines to drive rapid revenue growth; at the same time, economies of scale are becoming apparent, with deepened lean management, increased gross profit margins, and reduced period expense ratios, significantly enhancing profitability. As of December 31, 2025, Biocytogen Pharmaceuticals has signed over 350 drug cooperation development/licensing/transfer agreements. The company's sub-brand, Bai Ao Animals, has established thousands of gene-edited animal/cell models and boasts a globally leading collection of targeted humanized mouse models, providing global clients with comprehensive support for preclinical pharmacology and efficacy research, gene editing services, and model construction.